Scholarlink

The wide application of recombinant human erythropoietin (r-HuEPO) among the patients with chronic kidney disease (CKD) can bring about a rare but sever complication called anti-EPO antibody mediated pure red cell aplasia (PRCA). Once diagnosed, r-HuEPO administration should be discontinued immediately. However, after the removal of the anti-EPO antibody, it is still difficult for us to choose a nephrogenic anemia treatment for these CKD patients as restarting r-HuEPO therapy risks the recurrence of anti-EPO antibody mediated PRCA. A 78-year-old man with end-stage renal disease received r-HuEPO who developed anti-EPO PRCA unfortunately and his haemoglobin dropped continuously. During the removal of antibodies by treatment with corticosteroids and cyclosporine, therapy for nephrogenic anemia with roxadustat was prescribed at the meantime which led to a satisfactory result. Roxadustat is a kind of oral Hypoxia-inducible factor-Prolyl hydroxylase inhibitor which is developed for anemia treatment. This case reveals the potential effect of Roxadustat on anti-EPO PRCA.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anti-Erythropoietin Antibody-Mediated Pure Red Cell Aplasia

  • 章节

  • 出版模式：

    开放获取

  • 发表日期：

    2025年

查看全文
  • Jiayi Lv,
  • Zhiguo Mao

摘要

The wide application of recombinant human erythropoietin (r-HuEPO) among the patients with chronic kidney disease (CKD) can bring about a rare but sever complication called anti-EPO antibody mediated pure red cell aplasia (PRCA). Once diagnosed, r-HuEPO administration should be discontinued immediately. However, after the removal of the anti-EPO antibody, it is still difficult for us to choose a nephrogenic anemia treatment for these CKD patients as restarting r-HuEPO therapy risks the recurrence of anti-EPO antibody mediated PRCA. A 78-year-old man with end-stage renal disease received r-HuEPO who developed anti-EPO PRCA unfortunately and his haemoglobin dropped continuously. During the removal of antibodies by treatment with corticosteroids and cyclosporine, therapy for nephrogenic anemia with roxadustat was prescribed at the meantime which led to a satisfactory result. Roxadustat is a kind of oral Hypoxia-inducible factor-Prolyl hydroxylase inhibitor which is developed for anemia treatment. This case reveals the potential effect of Roxadustat on anti-EPO PRCA.